ADVERSE EVENTS IN PATIENTS WITH METASTATIC PANCREATIC CANCER RECEIVING LIPOSOMAL IRINOTECAN: UNDERSTANDING THE OCCURRENCE AND HOW MANAGEMENT AFFECTS PATIENT OUTCOMES

被引：0
|
作者：
Jameson, Gayle [1 ]
Caldwell, Lana [1 ]
Mirakhur, Beloo [2 ]
de Jong, Floris [3 ]
Ansaldo, Karen [1 ]
机构：
[1] HonorHealth, Scottsdale, AZ USA
[2] Ipsen Biopharmaceut, Basking Ridge, NJ USA
[3] Shire GmbH, Zug, Switzerland
来源：
ONCOLOGY NURSING FORUM | 2018年 / 45卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IS-15
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.
    Pijnappel, Esther
    de Vos-Geelen, Judith
    Macarulla Mercade, Teresa
    Melisi, Davide
    Pfeiffer, Per
    Prager, Gerald W.
    Van Laarhoven, Hanneke W. M.
    Wilmink, Johanna
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Nursing care and management of adverse events for patients with BRAFV600E-mutant metastatic colorectal cancer receiving encorafenib in combination with cetuximab: a review
    Matthew Fowler
    Helene Tobback
    Alice Karuri
    Paz Fernández-Ortega
    Supportive Care in Cancer, 2023, 31
  • [43] Nursing care and management of adverse events for patients with BRAFV600E-mutant metastatic colorectal cancer receiving encorafenib in combination with cetuximab: a review
    Fowler, Matthew
    Tobback, Helene
    Karuri, Alice
    Fernandez-Ortega, Paz
    SUPPORTIVE CARE IN CANCER, 2023, 31 (04)
  • [44] Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens
    Marks, Eric I.
    Matera, Robert
    Olszewski, Adam J.
    Yakirevich, Evgeny
    El-Deiry, Wafik S.
    Safran, Howard
    Carneiro, Benedito A.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (02): : 68 - 73
  • [45] Validation of the NCI patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in women receiving treatment for metastatic breast cancer
    Mitchell, Sandra A.
    Lang, Kathy
    Nichols, Christine
    Clauser, Steven B.
    Federico, Victoria
    Lalla, Deepa
    Tripathy, Debu
    Hurvitz, Sara A.
    Castro, Kathleen M.
    Reeve, Bryce B.
    Rogak, Lauren J.
    Denicoff, Andrea
    Chen, Alice
    Piekarz, Richard
    Bennett, Antonia V.
    Atkinson, Thomas Michael
    O'Mara, Ann M.
    Minasian, Lori M.
    Basch, Ethan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis
    Ge, Pu
    Han, Chunyan
    Reyila, Abudurousuli
    Liu, Diyue
    Hong, Wenying
    Liu, Jiaxin
    Zhang, Jinzi
    Han, Xiao
    Li, Xialei
    Huang, Mengjie
    Fan, Siyuan
    Kaierdebieke, Ayidana
    Wu, Xiaoyu
    Huang, Xiaolu
    Guo, Weirui
    Liu, Siyu
    Bian, Ying
    MEDICINE, 2023, 102 (35) : E34793
  • [47] Optimizing the management of immune- related adverse events and survival in patients with thoracic cancer receiving immunotherapy through artificial intelligence (electronic patient-reported outcomes): The IMPATHI study
    Amouin, Serge
    Brureau, Laurent
    Parnot, Charles
    Picchi, Hugo
    Le Roy, Audrey
    Barhli, Aline
    Audisio, Marie-Anne
    Pautas, Marie
    Brezun, Juliette
    Schernberg, Antoine
    Vanquaethem, Helene
    Helissey, Carole
    BULLETIN DU CANCER, 2025, 112 (02) : 149 - 156
  • [48] Handling of symptomatic adverse events in breast cancer patients receiving adjuvant chemotherapy in a cluster randomized trial with electronic patient-reported outcomes as intervention
    Baeksted, Christina W.
    Nissen, Aase
    Knoop, Ann
    Christiansen, Marianne
    Pappot, Helle
    BREAST JOURNAL, 2019, 25 (06): : 1295 - 1296
  • [49] Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group
    Yoo, Changhoon
    Im, Hyeon-Su
    Kim, Kyu-pyo
    Oh, Do-Youn
    Lee, Kyung-Hun
    Chon, Hong Jae
    Kim, Joo Hoon
    Kang, Myoungjoo
    Kim, Ilhwan
    Lee, Guk Jin
    Oh, Sung Yong
    Choi, Younak
    Choi, Hye Jin
    Kim, Seung Tae
    Park, Joon Oh
    Ryoo, Baek-Yeol
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [50] Observational retrospective evaluation of treatment with liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic cancer patients: An Italian large real-world analysis
    Pellino, Antonio
    Manai, Chiara
    Merz, Valeria
    Scartozzi, Mario
    Milella, Michele
    De Vita, Ferdinando
    Antonuzzo, Lorenzo
    Zichi, Clizia
    Satolli, Maria Antonietta
    Panebianco, Michele
    Noventa, Silvia
    Giordano, Guido
    Nappo, Floriana
    Zecchetto, Camilla
    Puzzoni, Marco
    Vaccaro, Vanja
    Pappalardo, Annalisa
    Giommoni, Elisa
    Melisi, Davide
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345